Whether CD47/SIRPα is a critical immune checkpoint target for the development of adjuvant immunotherapy policies, aiming to improve the cure rates in operable NSCLC should be investigated in clinical studies. The gene discussed is SIRPA; the disease is non-small cell lung carcinoma.